abstinence-associated depressive symptom worsening

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34